Vigil Vaccine For Ewing’s Sarcoma

VIGIL is the first immunotherapy trial designed specifically for Ewing sarcoma patients. A new cohort to the EWING VIGIL VACCINE TRIAL has recently opened and is recruiting patients at Mary Crowley, Cleveland Clinic and Memorial Sloan Kettering.

Click here to learn more:

A Two-part Phase IIb Trial of Vigil in Ewing Sarcoma